🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 14 of 173

  1. US 11957754

    Clinical formulations

    Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11957655

    Methods of treating hearing loss

    Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11958901

    Anti-CXCR5 antibodies and compositions and uses thereof

    Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11952379

    Small molecule modulators of PAR2 and uses thereof

    Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11952362

    Compositions and methods for treating epigenetic disease

    Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11951227

    Nanofiber structures and methods of use thereof

    Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11951118

    Preparation of preliposomal annamycin lyophilizate

    Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11951176

    Stabilization of glucagon by trehalose glycopolymer nanogels

    Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11952366

    Substituted 1,3,5-triazines as inhibitors for a rho family of GTP-ases

    Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11952330

    Antibiotic ammonium compounds and methods for the treatment of bacterial infections

    Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11944532

    Engineered tendon graft for rotator cuff repair

    Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11944626

    Small molecule inhibitors of ALDH and uses thereof

    Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11944679

    Genome-wide identification of immune evasion functions in a virus

    Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11946065

    Transgene cassettes, AAV vectors, and AAV viral vectors for expression of human codon-optimized CSTB

    Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11944614

    Imidazo[4,5-c]pyridine compounds as LSD-1 inhibitors

    Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11946049

    tRNA/pre-miRNA compositions and use in treating cancer

    Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11938218

    High density peptide polymers

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11938171

    Therapeutic systems, devices, and compositions with wound healing and tissue regenerative properties, uses thereof, and corresponding methods

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11938148

    Treatment of neurodegenerative disease with sodium chlorite

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11939370

    Pan-ebola virus neutralizing human antibodies and methods of use therefor

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11939379

    Antibody chemically induced dimerizer (AbCID) as molecular switches for regulating cellular therapies

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11938226

    Abiotic anti-VEGF nanoparticle

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11938150

    Treatment of neurodegenerative disease with sodium chlorite

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11938233

    1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11938147

    Treatment of neurodegenerative disease with sodium chlorite

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11939591

    Genetically modified MSC and therapeutic methods

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11938149

    Treatment of neurodegenerative disease with sodium chlorite

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11931480

    Microporous annealed particle gels and methods of use

    Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11932867

    Methods of treating rheumatoid arthritis using RNA-guided genome editing of HLA gene

    Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11932856

    RNA targeting of mutations via suppressor tRNAs and deaminases

    Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11931481

    Microporous annealed particle gel system

    Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11933781

    Fibrosis model and methods of use thereof

    Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11932606

    Anti-cancer/anti-fibrosis compounds

    Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11931386

    Compositions and methods for increasing butyrate production

    Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11932628

    Selective small molecule peptidomimetic melanocortin ligands

    Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11931460

    Aminoglycoside antibiotic-derived microbead-encapsulated spheroids and methods of making and using the same

    Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11925679

    H3.3 CTL peptides and uses thereof

    Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11926824

    miRNA biogenesis in exosomes for diagnosis and therapy

    Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11926826

    Twist signaling inhibitor compositions and methods of using the same

    Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11925654

    Esters of 2-deoxy-monosaccharides with anti proliferative activity

    Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11925642

    Regulation of eIF4E activity for migraine therapy

    Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11925649

    Treatments for diabetic neuropathy

    Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11925623

    Methods for the treatment of conditions related to hydrogen sulfide

    Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11919880

    HCV protease inhibitors

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11918686

    Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11918770

    Implants for localized drug delivery and methods of use thereof

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11920139

    Regulated expression of antigen and/or regulated attenuation to enhance vaccine immunogenicity and/or safety

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11919933

    Use of MYOG gene as target in preparation of drug for treating cardiomyocyte apoptosis-associated cardiovascular disease

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.